from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. An anticonvulsant that inhibits the catabolism of GABA by irreversibly inhibiting GABA transaminase.


Sorry, no etymologies found.


  • Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects e.g., visual field defects, or VFDs from those associated with vigabatrin.

    Catalyst Pharmaceutical Partners to Present at the Biotech Showcase(TM) 2011 Conference - Yahoo! Finance

  • The presentation discussed the medical relevance of GABA aminotransferase inactivators in the treatment of epilepsy and drug addiction, the history of the discovery of CPP-115, a detailed mechanistic analysis of GABA-AT inactivators, and a summary of CPP-115's pharmacological properties, including its superior visual safety profile and potency compared to vigabatrin.

  • Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 vigabatrin, for the treatment of cocaine addiction.

  • Keppra or levetiracetam, H. Lundbeck's Sabril or vigabatrin, Pfizer's Neurontin or gabapentin and Lyrica or pregabalin, GlaxoSmithKline's Lamictal or lamotrigine, Novartis 'Trileptal or oxcarbazepine and Eisai's Zonegran or zonisamide.

    Toronto Sun

  • Phase II trial evaluating CPP-109, Catalyst's form of vigabatrin, to treat cocaine addiction. Featured News and Stories

  • Phase II (b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. News Articles

  • By the end of the third quarter of 2010, most of the safety studies described above, including results from assessments of the comparative retinotoxicity of CPP-115 versus vigabatrin, are expected to be completed.

    RedOrbit News - Technology

  • The visual safety of CPP-115 will be evaluated and compared to the only FDA approved GABA aminotransferase inhibitor drug, vigabatrin.

    RedOrbit News - Technology

  • The increased potency could enable the development of superior or alternative dosage forms and routes of administration compared with the marketed version of vigabatrin, Sabril® (which is marketed in the U.S. by Lundbeck Inc. for infantile spasms and refractory complex partial seizures).

    RedOrbit News - Technology

  • Catalyst also in-licensed worldwide rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries.

    RedOrbit News - Technology


Log in or sign up to get involved in the conversation. It's quick and easy.